NCT05505409View on ClinicalTrials.gov

Efficacy and Safety of Pirfenidone in CTD-ILD

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 1, 2025

Conditions
PirfenidoneConnective Tissue DiseasesInterstitial Lung Disease
Interventions
DRUG

Pirfenidone

Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease

DRUG

glucocorticoid and immunosuppressant

Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease

Trial Locations (1)

250012

RECRUITING

Qilu Hospital, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT05505409 - Efficacy and Safety of Pirfenidone in CTD-ILD | Biotech Hunter | Biotech Hunter